Non-Invasive VeriCor® Monitor Could Control Heart
New Noninvasive Monitor
Enhances Efficacy of Heart Failure Treatment.
The FDA-cleared VeriCor® monitor
is a non-invasive hemodynamic monitor that can accurately
measure LVEDP (left ventricular end-diastolic pressure).
LVEDP is the pressure of blood entering the heart from
the lungs. It is the primary determinant of the presence
and severity of heart failure (HF) and the best indicator
of the efficacy of HF treatment. When LVEDP levels are
abnormally elevated, the risks of hospitalization and
death are high. Treatment guided by the VeriCor®
monitor can reduce LVEDPs to levels at which the risks
of hospitalization and death are minimal.
Accuracy of VeriCor®
Monitor for LVEDP Superior to Catheters Used in Hospital
Now that the VeriCor® has proven
to be more accurate for LVEDP than catheters used to
guide HF treatment in hospital ICUs, it can be used
to reduce abnormally elevated LVEDPs and minimize HF
deaths, hospitalizations and care-costs in the 5 million
HF patients in the U.S.
Potential Human & Financial
Benefits of VeriCor® Monitor-Guided HF Treatment
By maintaining LVEDP levels in the
normal/near-normal range (<20mmHg), the VeriCor®
monitor could prevent 700,000 hospitalizations and 150,000
HF deaths while saving $16 to $18 billion in financial
resources that would otherwise be consumed by ineffective
Impact of the Vericor®
monitor on individual states.
HF deaths will be reduced by >1,000/year
in 39 states, HF hospitalizations will be reduced by
>5,000 in 34 states and care costs will be reduced
by $100 millon/year in 38 states.
& Control of Heart Failure (HF)
Elevated heart pressures (LVEDPs) cause HF deaths &
high care costs. Treatment reduces elevated LVEDPs,
HF deaths & care costs.
Monitor Shows HF Care Is Ineffective
VeriCor® monitor proves current approach to HF Care
leads to most HF deaths and costs.
Favor VeriCor® for HF Care
Majority of cardiologists surveyed favor VeriCor®
for HF care.
Could Control HF in U.S.
Many HF patients are at increased risk of death &
hospitalization in 1 year. VeriCor® reduces these
HF in Connecticut
VeriCor® could prevent 3,134 HF deaths,
9,519 hospitalizations and save $133 million a year.
HF in Massachusetts
VeriCor® could prevent 14,222 hospitalizations and
save $307 million a year.
VeriCor® could prevent > 4,800 deaths in 12 states
and save > $300 million in 19 states.
from All Monitoring Venues
CVP revenues from all monitoring venues could reach
$87 billion a year.
from Home Monitoring
CVP revenues from home monitoring alone could reach
$30 billion a year.
VeriCor® Poised to Control HF
VeriCor® could prevent as many as 15,000 deaths
and save up to $1 billion a year in US.